ID
ARRY

Integral Derivatives’s Array Biopharma Inc ARRY Stock Holding History

Integral Derivatives’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,300
Closed -$349K – 1149
2017
Q4 		$349K Buy
27,300
+11,500
+73% +$131K 0.01% 828
2017
Q3 		$194K Sell
15,800
-400
-2% -$3.71K ﹤0.01% 1022
2017
Q2 		$136K Buy
+16,200
New +$132K ﹤0.01% 1021
2017
Q1 		– Sell
-15,900
Closed -$140K – 1458
2016
Q4 		$140K Buy
15,900
+2,300
+17% +$16.9K ﹤0.01% 1046
2016
Q3 		$92K Buy
+13,600
New +$52.6K ﹤0.01% 947
2014
Q3 		– Sell
-12,300
Closed -$56K – 1610
2014
Q2 		$56K Hold
12,300
– – ﹤0.01% 1291
2014
Q1 		$58K Buy
+12,300
New +$61.8K ﹤0.01% 1252

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Integral Derivatives's ARRY Position: Q2 2014 in Review

Integral Derivatives sold out of Array Biopharma Inc (ARRY) in Q2 2014, closing a stake of 21,612 shares — an estimated $89.4K sold.

Integral Derivatives first reported a position in ARRY in Q4 2013 and held it in 2 quarters. The position peaked at $104K in Q4 2013. 129 funds tracked by Wall St. Rank hold ARRY as of Q2 2014.

  • Integral Derivatives reported no remaining Array Biopharma Inc position as of Q2 2014 after selling out during the quarter.
  • Integral Derivatives sold 21,612 Array Biopharma Inc shares in Q2 2014, an estimated $89.4K.
  • Integral Derivatives first reported a position in Array Biopharma Inc in Q4 2013 and held it in 2 quarters.
  • Integral Derivatives's Array Biopharma Inc position peaked at $104K in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2014.

Based on Integral Derivatives's 13F filing for Q2 2014, filed 7 Aug 2014.